¢¸
  • ¼Ò¾Æ¿¡¼­ ¼öµÎ ¿¹¹æ Á¢Á¾¾Æ¿Í °¨¿° ¸é¿ª¾ÆÀÇ ¼öµÎ ƯÀÌ IgG Ȳü°¡¿¡ ´ëÇÑ ¿¬±¸   (1 ÆäÀÌÁö)
    1

  • ¼Ò¾Æ¿¡¼­ ¼öµÎ ¿¹¹æ Á¢Á¾¾Æ¿Í °¨¿° ¸é¿ª¾ÆÀÇ ¼öµÎ ƯÀÌ IgG Ȳü°¡¿¡ ´ëÇÑ ¿¬±¸   (2 ÆäÀÌÁö)
    2

  • ¼Ò¾Æ¿¡¼­ ¼öµÎ ¿¹¹æ Á¢Á¾¾Æ¿Í °¨¿° ¸é¿ª¾ÆÀÇ ¼öµÎ ƯÀÌ IgG Ȳü°¡¿¡ ´ëÇÑ ¿¬±¸   (3 ÆäÀÌÁö)
    3

  • ¼Ò¾Æ¿¡¼­ ¼öµÎ ¿¹¹æ Á¢Á¾¾Æ¿Í °¨¿° ¸é¿ª¾ÆÀÇ ¼öµÎ ƯÀÌ IgG Ȳü°¡¿¡ ´ëÇÑ ¿¬±¸   (4 ÆäÀÌÁö)
    4

  • ¼Ò¾Æ¿¡¼­ ¼öµÎ ¿¹¹æ Á¢Á¾¾Æ¿Í °¨¿° ¸é¿ª¾ÆÀÇ ¼öµÎ ƯÀÌ IgG Ȳü°¡¿¡ ´ëÇÑ ¿¬±¸   (5 ÆäÀÌÁö)
    5

  • ¼Ò¾Æ¿¡¼­ ¼öµÎ ¿¹¹æ Á¢Á¾¾Æ¿Í °¨¿° ¸é¿ª¾ÆÀÇ ¼öµÎ ƯÀÌ IgG Ȳü°¡¿¡ ´ëÇÑ ¿¬±¸   (6 ÆäÀÌÁö)
    6

  • ¼Ò¾Æ¿¡¼­ ¼öµÎ ¿¹¹æ Á¢Á¾¾Æ¿Í °¨¿° ¸é¿ª¾ÆÀÇ ¼öµÎ ƯÀÌ IgG Ȳü°¡¿¡ ´ëÇÑ ¿¬±¸   (7 ÆäÀÌÁö)
    7


  • º» ¹®¼­ÀÇ
    ¹Ì¸®º¸±â´Â
    7 Pg ±îÁö¸¸
    °¡´ÉÇÕ´Ï´Ù.
¢º
Ŭ¸¯ : ´õ Å©°Ôº¸±â
  • ¼Ò¾Æ¿¡¼­ ¼öµÎ ¿¹¹æ Á¢Á¾¾Æ¿Í °¨¿° ¸é¿ª¾ÆÀÇ ¼öµÎ ƯÀÌ IgG Ȳü°¡¿¡ ´ëÇÑ ¿¬±¸   (1 ÆäÀÌÁö)
    1

  • ¼Ò¾Æ¿¡¼­ ¼öµÎ ¿¹¹æ Á¢Á¾¾Æ¿Í °¨¿° ¸é¿ª¾ÆÀÇ ¼öµÎ ƯÀÌ IgG Ȳü°¡¿¡ ´ëÇÑ ¿¬±¸   (2 ÆäÀÌÁö)
    2

  • ¼Ò¾Æ¿¡¼­ ¼öµÎ ¿¹¹æ Á¢Á¾¾Æ¿Í °¨¿° ¸é¿ª¾ÆÀÇ ¼öµÎ ƯÀÌ IgG Ȳü°¡¿¡ ´ëÇÑ ¿¬±¸   (3 ÆäÀÌÁö)
    3

  • ¼Ò¾Æ¿¡¼­ ¼öµÎ ¿¹¹æ Á¢Á¾¾Æ¿Í °¨¿° ¸é¿ª¾ÆÀÇ ¼öµÎ ƯÀÌ IgG Ȳü°¡¿¡ ´ëÇÑ ¿¬±¸   (4 ÆäÀÌÁö)
    4

  • ¼Ò¾Æ¿¡¼­ ¼öµÎ ¿¹¹æ Á¢Á¾¾Æ¿Í °¨¿° ¸é¿ª¾ÆÀÇ ¼öµÎ ƯÀÌ IgG Ȳü°¡¿¡ ´ëÇÑ ¿¬±¸   (5 ÆäÀÌÁö)
    5

  • ¼Ò¾Æ¿¡¼­ ¼öµÎ ¿¹¹æ Á¢Á¾¾Æ¿Í °¨¿° ¸é¿ª¾ÆÀÇ ¼öµÎ ƯÀÌ IgG Ȳü°¡¿¡ ´ëÇÑ ¿¬±¸   (6 ÆäÀÌÁö)
    6

  • ¼Ò¾Æ¿¡¼­ ¼öµÎ ¿¹¹æ Á¢Á¾¾Æ¿Í °¨¿° ¸é¿ª¾ÆÀÇ ¼öµÎ ƯÀÌ IgG Ȳü°¡¿¡ ´ëÇÑ ¿¬±¸   (7 ÆäÀÌÁö)
    7



  • º» ¹®¼­ÀÇ
    (Å« À̹ÌÁö)
    ¹Ì¸®º¸±â´Â
    7 Page ±îÁö¸¸
    °¡´ÉÇÕ´Ï´Ù.
´õºíŬ¸¯ : ´Ý±â
X ´Ý±â
µå·¡±× : Á¿ìÀ̵¿

¼Ò¾Æ¿¡¼­ ¼öµÎ ¿¹¹æ Á¢Á¾¾Æ¿Í °¨¿° ¸é¿ª¾ÆÀÇ ¼öµÎ ƯÀÌ IgG Ȳü°¡¿¡ ´ëÇÑ ¿¬±¸

·¹Æ÷Æ® > ÀǾຸ°Ç ÀÎ ¼â ¹Ù·Î°¡±âÀúÀå
Áñ°Üã±â
Å°º¸µå¸¦ ´­·¯ÁÖ¼¼¿ä
( Ctrl + D )
¸µÅ©º¹»ç
Ŭ¸³º¸µå¿¡ º¹»ç µÇ¾ú½À´Ï´Ù.
¿øÇÏ´Â °÷¿¡ ºÙÇô³Ö±â Çϼ¼¿ä
( Ctrl + V )
ÆÄÀÏ : ¼Ò¾Æ¿¡¼­ ¼öµÎ ¿¹¹æ Á¢Á¾¾Æ¿Í °¨¿° ¸é¿ª¾ÆÀÇ ¼öµÎ ƯÀÌ~.hwp   [Size : 60 Kbyte ]
ºÐ·®   7 Page
°¡°Ý  1,000 ¿ø

Ä«Ä«¿À ID·Î
´Ù¿î ¹Þ±â
±¸±Û ID·Î
´Ù¿î ¹Þ±â
ÆäÀ̽ººÏ ID·Î
´Ù¿î ¹Þ±â


ÀÚ·á¼³¸í
¼öµÎ´Â ½Å»ý¾Æ¸¦ Æ÷ÇÔÇÏ¿© ¾î´À ¿¬·É¿¡¼­³ª ¹ß»ýÇÏ´Â ÁúȯÀ¸·Î È£Èí±â³ª Á÷Á¢ÀûÀÎ Á¢ÃËÀ» ÅëÇØ ±Þ¼ÓÈ÷ À¯ÇàÀ» ÀÏÀ¸Å°¸ç, °¨¼ö¼º ÀÖ´Â °¡Á·³» Á¢ÃËÀÚÀÇ ...
º»¹®/³»¿ë
¼öµÎ´Â ½Å»ý¾Æ¸¦ Æ÷ÇÔÇÏ¿© ¾î´À ¿¬·É¿¡¼­³ª ¹ß»ýÇÏ´Â ÁúȯÀ¸·Î È£Èí±â³ª Á÷Á¢ÀûÀÎ Á¢ÃËÀ» ÅëÇØ ±Þ¼ÓÈ÷ À¯ÇàÀ» ÀÏÀ¸Å°¸ç, °¨¼ö¼º ÀÖ´Â °¡Á·³» Á¢ÃËÀÚÀÇ ÀÌÂ÷Àû °¨¿°À²ÀÌ 90%¶ó°í º¸°í ÇÏ¿´´Ù1). À̵é Áß ´ëºÎºÐÀÌ 10¼¼ ¹Ì¸¸À̸ç 3¼¼¿¡¼­ 6¼¼ »çÀÌ¿¡ °¡Àå Å« À¯º´À²À» °¡Áø´Ù°í ÇÏ¿´°í2,3) 10¼¼ ¹Ì¸¸ÀÇ ¾î¸°ÀÌ 90%À̻󿡼­ ÀÌȯ µÇ¾îÁú »Ó¾Æ´Ï¶ó ƯÈ÷ »ýÈÄ Ã¹ 6°³¿ù µ¿¾ÈÀº ´Ù¸¥ ¹ÙÀÌ·¯½º °¨¿°º¸´Ù ´õ ¸¹ÀÌ ¹ß»ýµÈ´Ù.
¼öµÎ Ç×ü´Â ÀӽŠÁß ¸ðü·ÎºÎÅÍ Å¹ÝÀ» ÅëÇØ Å¾ƿ¡°Ô Àü´Þ µÇÁö¸¸ »ýÈÄ ±Þ°ÝÈ÷ °¨¼ÒÇÏ¿© 6°³¿ù¿¡¼­ 1³â »çÀÌ¿¡ ÀÌÇà Ç×ü°¡ À½¼ºÀ» ³ªÅ¸³»¸ç4), º» ¿¬±¸¿¡¼­µµ ´ëÁ¶±º¿¡¼­ 6°³Àª¿¡¼­ 1¼¼ »çÀÌÀÇ È¯¾Æ 57¸í Áß ÀÌÇà Ç×ü(transferred antibody)°¡ À½¼ºÀ» ³ªÅ¸³½ °æ¿ì´Â 51¸íÀ¸·Î 89.5%¸¦ Â÷ÁöÇÏ¿´´Ù. ±×·¯³ª °Ç°­¾Æ »Ó¸¸ ¾Æ´Ï¶ó ¸é¿ª °áÇ̼º ȺÀÚ¿¡¼­´Â ³ôÀº ÀÌȯÀ²°ú ÇÔ²² »ç¸Á¿¡±îÁö À̸£·¯5), ¸é¿ª °¨¼ö¼º ȯÀÚ¿¡¼­ÀÇ ½ÉÇÑ ¼öµÎ¸¦ ¿¹¹æÇϱâ À§ÇØ varicella-zoster ¸é¿ª ±Û·Îºí¸°À» ÀÌ¿ëÇÑ ¼öµ¿ÀûÀÎ ¸é¿ª¹ýÀÌ »ç¿ëµÇ¾úÀ¸³ª6) ºñ°æÁ¦ÀûÀÌ°í VZV¿¡ ³ëÃâµÈ ÈÄ¿¡ »ç¿ëµÈ´Ù´Â ´ÜÁ¡ÀÌ ÀÖ´Ù.
µû¶ó¼­ ¼öµÎ¸¦ ¿¹¹æÇϱâ À§ÇØ 1974³â ÀϺ»¿¡¼­ óÀ½À¸·Î ¡¦(»ý·«)
Âü°í¹®Çå
1) Ross AH, Lencher E, Reitman G: Modification of chickenpox in family contacts by administration of gamma globulin. N Engl J Med 267:369-376, 1962
2) Rivers TM, Eldridge LA: Relation of varicella to herpes zoster. I, Statistical observations.¥± (1929), Clinical and experimental observations. J Exp Med 49:899-917, 1929
3) Gordon JE: Chickenpox: An epidemiologic review. Am J Med Sci 244:362-38Q 1962
4) Gershon AA, Raker R, Steinberg S, Topf-Olstein B, Drnsin LM: Antibody to varicella-zoster virus in parturients woman and their offspring during the first year of life. Pediatrics 692-696, 1976
5) Feldman S, Hughes WT, Danial CB: Varicella in children with cancer: Seventy-seven cases. Pediatrics 80:388-397 1975
6) Zala JA, Levin MJ, Freblud SR, Leszczynski J, Wright GG, Ellis RJ, Curtis AC, Valerio HA, LiGore J: Evaluation of varicella-zoster immunoglobulin: Protection of immunosuppressed children after household exposure to varicella. J Infec Dis 147:737-742, 1983
7) Takahashi M: Current status and prospects of live varicella vaccin. Vaccine 10:1007-1014, 1992
8) Takanashi M, Kanniya H, Baba K, Asana Y, Ozaki T, Horiuchi K: Clinical experience with Oka live varicella vaccine in Japan. Postgrad Med J 61:61-67, 1985
9) Gershon AA, Steinberg SP, Gelb L, Galasso C, Borkowski W, LsRussa P, Ferrera A, MAID: Live varicella vaccine: Efficacy for children with leukemia in remission. J Am Med Assoc 252:355-362, 1984
10) Gershon AA, LaRUssa P, Steinberg SP: Live attenuated varicella vaccine: Current status and future uses. Sem Ped Intec Dis 2:171-178, 1991
11) Gershon AA, LaRussa P, Hardy I, Steinberg S, Silverstein S: Varicella vaccine: The american experience. J Inf Dis 166:63-08, 1992
12) Arbeter AM, Granowetter L, Gelser C, Waugh JE: Administration of live varicella vaccine to chidren with leukemia Pediatrics 85:338-344, 1990
13) Brunell PA, Shehab Z, Gelser C, Waugh JE: Administration of live varicella vaccine to children with leuke- mia. Lancet 11:1069-1073, 1982
14) Srabstein JC, Morris N, Larke B, Lesa DJ, Castelino BB, Sum E: Is there a congenital varicella syndrome?. J Pediatr 84:239-243, 1974
15) Gershon AA, Steinberg S, LaRussa p: Rapid detection of immunity to varicella by latex agglutination. Ped Res 31:162A, 1991
16) Heidl M, Scholz H: Varicella vaccination Pediatrie and Grenrgebiete 29:31-36, 1990
17) Gershon AA: Human immune responses to live attenuated varicella vaccine. Reviews of Inf Dis 13:957-959, 1991
18)Fleisher G, Henry W, McSorley M, Arbeter A, Plotkin S: Life threatening complications varicella. Am J Dis Child 135:896-899, 1981
19) Ozaki T, Matsui T, Ichikawa T: Clinical trial of the OKA strain of live attenuated varicella vaccine on heal thy children. Biken J 2739-42, 1984
20) Arbeter AM, Starr SE, Preblud SR, Ihara T, Paciorek PM, Miller DS, Zelson CM, Proctor RA, Platkin SA: Varicella vaccine trials in healty children. AJDC 138:434-438,1984
21) White CJ, Kuter BJ, Hildebrand CS, Isganitis KL, Matthews H, Miller WJ, Provost PJ, Ellis RW, Gerety RJ, Calan dra GB: Varicella vaccine (VARIVAX) in healthy children and adolescents: Results from clinical trials, 1987 to 1989. Pediatrics 87:604-610, 1991
22) Weibel RE, Neff B, Kuter BJ, Guess HA, Rothenberger CA, Fitzgerald AJ, Connor KA, McLean AA, Hilleman MR, Buynak EB: Live attenuated varicella virus vaccine: Efficacy trial in healthy children. N Engl J Med 310:1409-1415,1984
23) Arbeter AM, Starr SE, Plotkin SA: Varicella vaccine studies in healthy children and adults. Pediatrics 78:748-756, 1986
24) Asano Y, Albrecht P, Vujcic LK, Quinnan GV, Kawakatni K, Takahashi M: Five-year follow-up study of recipients of live varicella vaccine using enhanced neutralization and fluorescent antibody membrane antigen assays. Pediatrics 72:291-294, 1983
25) Asano Y, Nagal T, Miyata T, Yataki T, Ito S, Yamanishi K, Takahashi M: Long-term protec tive immunity of recipients of the Oka strain of live varicella vaccine. Pediatrics 75:667-671, 1985
26) Johnson C, Rome L, Stancin T, Kumar M:
Humonal immunity and clinical reinfections follwing varicella vaccine in healthy children Pediatrics 84:418-421, 1989
27) Kuter BJ, Weibel RE, Guess HA, Matthews H, Morton OM, Neff BJ, Provost PJ, Watson BA, Stair SE, Plotkin SA: Oka/Merck varicella vaccine in healthy children: Final report of a 2-year efficacy study and 7-year follow studies.Vaccine 9:643-647, 1991
28) Diaz PS, Au D, Smith S, Amylon M, Link M, Smith S, Arvin AM: Lack of transmission of the live attenuated varicella viccine to immunocompromised children after immunization of their siblings. Pediatrics 87:166-170, 1991
29) Takahashi M, Asano Y, Karniya H, Baha K, Yamanishi K: Prevention and treatment of vancella zoster virus, presented at the International conference on human herpes virus, Emory University, March 20, 1980
30) White CJ: Varicella vaccine reflux. Reply. Pediatrics 89:354, 1992
31) Feldman S, Hughes WT, Kim HY: Herpes zoster in children with cancer. Am J Dis Child 126:178-184, 1973
32) Hardy I, Gershon AA, Steinberg SP, LaRuss p: The incidence of zoster after immunization with live attenuated varicella vaccine. New Eng J Med 325:1545-1550,1991
33) Lawrence R, Gershon A, Holzman R, Steinberg S, NIAID: The risk of zoster after varicella vaccination in children with leukemia. N Engl J Med 318:543-548, 1988
34) Feldman S, Lott L: Varicella in children with cancer. Impact of antivinal therapy and prophylaxis, Pediatrics 80:465-472, 1987
35) Gershon AA, Steinberg SP, National Institude of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group: Live attenuated varicella vaccine: Protection in healty adults compared with leukemic children. J Intect Dis 161:661-666, 1990
36) Russell AS, Maini RA, Bailey M, Dumone DC: Cell mediated immunity to varicella zoster antigen in acute herpes zoster. Clin Exp Immunol 14181-185, 1973
37) uckdeshel JC, Schimoff SC, Smyth AC, Mardiney MR: Herpes zoster and impaired cell associated immunity to the varicella zoster virus in patients with Hodgkin`s disease. Am J Med 62:77-85,1977
38) ¾ÈÈ¿¼·, ±èÁß°ï: ¾àµ¶È­µÈ »ý¼öµÎ ¹é½Å Á¢Á¾¿¡ µû¸¥ ±Þ¼º ¸³ÇÁ±¸¼º ¹éÇ÷º´ ȯ¾Æ¿¡ ¼­ÀÇ ¸é¿ªÇÐÀû ¹ÝÀÀ, ¼Ò¾Æ°ú 34:1255-1259, 1991
39) Schur PH: IgG subclass-a review. Ann Allergy 58:89-96, 1987
40) Morrell A, Roth-Wicky B, Skvaril F: Immunoglobulin G subclass restriction of antibodies against hepatitis B surface antigen. Infect Immunol 39:565-568, 1983
41) Linde GA: Subclass distribution of rubella virus specific immunoglobulin G. J Clin Microbiol 13:393-396, 1985
42) Coleman RM, Nahinias AJ, Williams SC: IgG subclass antibody to herpes simplex virus. J Intect Dis 151:929-936, 1985
43) Linde GA, Hammarstrom L, Persson M: Virus specific antibody activity of different subclass of immunoglobulin G and A in cytomegalovirus infections, Infect Immunol 42:237-244, 1983
44) Wager DK, Graham BS, Wright PF: Serum immunoglobulin G antibody subclass responses to respiratory syncitial virus F and G glycoproteins after primary infection. J Clin Microbiol 24:304-3O6, 1986


ÀÚ·áÁ¤º¸
ID : sypj*****
Regist : 2014-12-03
Update : 2014-12-03
FileNo : 16064447

Àå¹Ù±¸´Ï

¿¬°ü°Ë»ö(#)
¼Ò¾Æ   ¼öµÎ   ¿¹¹æ   Á¢Á¾¾Æ   °¨¿°   ¸é¿ª¾Æ   IgG   Ȳü°¡¿¡   ´ëÇÑ   ¿¬±¸  


ȸ»ç¼Ò°³ | ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸Ãë±Þ¹æħ | °í°´¼¾ÅÍ ¤Ó olle@olleSoft.co.kr
¿Ã·¹¼ÒÇÁÆ® | »ç¾÷ÀÚ : 408-04-51642 ¤Ó ±¤ÁÖ±¤¿ª½Ã ±¤»ê±¸ ¹«Áø´ë·Î 326-6, 201È£ | äÈñÁØ | Åë½Å : ±¤»ê0561È£
Copyright¨Ï ¿Ã·¹¼ÒÇÁÆ® All rights reserved | Tel.070-8744-9518
ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸Ãë±Þ¹æħ ¤Ó °í°´¼¾ÅÍ ¤Ó olle@olleSoft.co.kr
¿Ã·¹¼ÒÇÁÆ® | »ç¾÷ÀÚ : 408-04-51642 | Tel.070-8744-9518